Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing. / Rieneck, Klaus; Clausen, Frederik Banch; Dziegiel, Morten Hanefeld.

In: Cold Spring Harbor Perspectives in Medicine, Vol. 6, No. 1, a023093, 01.01.2016.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Rieneck, K, Clausen, FB & Dziegiel, MH 2016, 'Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing', Cold Spring Harbor Perspectives in Medicine, vol. 6, no. 1, a023093. https://doi.org/10.1101/cshperspect.a023093

APA

Rieneck, K., Clausen, F. B., & Dziegiel, M. H. (2016). Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing. Cold Spring Harbor Perspectives in Medicine, 6(1), [a023093]. https://doi.org/10.1101/cshperspect.a023093

Vancouver

Rieneck K, Clausen FB, Dziegiel MH. Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing. Cold Spring Harbor Perspectives in Medicine. 2016 Jan 1;6(1). a023093. https://doi.org/10.1101/cshperspect.a023093

Author

Rieneck, Klaus ; Clausen, Frederik Banch ; Dziegiel, Morten Hanefeld. / Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing. In: Cold Spring Harbor Perspectives in Medicine. 2016 ; Vol. 6, No. 1.

Bibtex

@article{30ae9d41b80443d0aa269aeffdc2d841,
title = "Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing",
abstract = "Hemolytic disease of the fetus and newborn (HDFN) is a condition characterized by a decreased lifespan of fetal red blood cells caused by maternally produced allospecific antibodies transferred to the fetus during pregnancy. The antibodies bind to the corresponding blood group antigens on fetal red blood cells and induce hemolysis. Cell-free DNA derived fromthe conceptus circulates in maternal blood. Using next-generation sequencing (NGS), it can be determined if this cell-free fetalDNA encodes the corresponding blood group antigen that is the target of the maternal allospecific antibodies. This determination carries no risk to the fetus. It is important to determine if the fetus is at risk of hemolysis to enable timely intervention. Many tests for blood groups are based solely on the presence or absence of a single nucleotide polymorphism (SNP). Antenatal determination of fetal blood group byNGS analysis holds advantages over polymerase chain reaction (PCR) determination based on allele specific amplification.",
author = "Klaus Rieneck and Clausen, {Frederik Banch} and Dziegiel, {Morten Hanefeld}",
year = "2016",
month = jan,
day = "1",
doi = "10.1101/cshperspect.a023093",
language = "English",
volume = "6",
journal = "Cold Spring Harbor Perspectives in Medicine",
issn = "2157-1422",
publisher = "Cold Spring Harbor Laboratory Press",
number = "1",

}

RIS

TY - JOUR

T1 - Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing

AU - Rieneck, Klaus

AU - Clausen, Frederik Banch

AU - Dziegiel, Morten Hanefeld

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Hemolytic disease of the fetus and newborn (HDFN) is a condition characterized by a decreased lifespan of fetal red blood cells caused by maternally produced allospecific antibodies transferred to the fetus during pregnancy. The antibodies bind to the corresponding blood group antigens on fetal red blood cells and induce hemolysis. Cell-free DNA derived fromthe conceptus circulates in maternal blood. Using next-generation sequencing (NGS), it can be determined if this cell-free fetalDNA encodes the corresponding blood group antigen that is the target of the maternal allospecific antibodies. This determination carries no risk to the fetus. It is important to determine if the fetus is at risk of hemolysis to enable timely intervention. Many tests for blood groups are based solely on the presence or absence of a single nucleotide polymorphism (SNP). Antenatal determination of fetal blood group byNGS analysis holds advantages over polymerase chain reaction (PCR) determination based on allele specific amplification.

AB - Hemolytic disease of the fetus and newborn (HDFN) is a condition characterized by a decreased lifespan of fetal red blood cells caused by maternally produced allospecific antibodies transferred to the fetus during pregnancy. The antibodies bind to the corresponding blood group antigens on fetal red blood cells and induce hemolysis. Cell-free DNA derived fromthe conceptus circulates in maternal blood. Using next-generation sequencing (NGS), it can be determined if this cell-free fetalDNA encodes the corresponding blood group antigen that is the target of the maternal allospecific antibodies. This determination carries no risk to the fetus. It is important to determine if the fetus is at risk of hemolysis to enable timely intervention. Many tests for blood groups are based solely on the presence or absence of a single nucleotide polymorphism (SNP). Antenatal determination of fetal blood group byNGS analysis holds advantages over polymerase chain reaction (PCR) determination based on allele specific amplification.

UR - http://www.scopus.com/inward/record.url?scp=84953284860&partnerID=8YFLogxK

U2 - 10.1101/cshperspect.a023093

DO - 10.1101/cshperspect.a023093

M3 - Journal article

C2 - 26511760

AN - SCOPUS:84953284860

VL - 6

JO - Cold Spring Harbor Perspectives in Medicine

JF - Cold Spring Harbor Perspectives in Medicine

SN - 2157-1422

IS - 1

M1 - a023093

ER -

ID: 186449639